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ABSTRACT
Background: Dystroglycanopathies are a group of congenital muscular dystrophies (CMDs) with
autosomal recessive inheritance, often associated with CNS and ocular involvement. They are
characterized by the abnormal glycosylation of alpha-dystroglycan, and caused bymutations in at
least six genes encoding enzymes: FKTN, POMGNT1, POMT1, POMT2, FKRP, and LARGE.
POMT2 mutations have recently been identified in Walker-Warburg syndrome and in a milder
muscle-eye-brain disease-like form.
Methods: We studied mentally retarded patients with CMD, analyzed POMT2 by sequencing the
coding regions, and also performed a haplotype analysis in all patients and their family members
carrying the new POMT2 mutation.
Results: We report three novel POMT2 mutations. One of these, p.Tyr666Cys, was homozygous
in two unrelated patients and in a compound heterozygous state in others. All patients showed
severe diffuse muscle weakness, microcephaly, severe mental retardation, and marked lordosco-
liosis with hyperextended head. Elevated CK levels, cerebral cortical atrophy, and cerebellar ver-
mis hypoplasia were constant findings. Mild cardiac abnormalities, focal white matter
abnormalities, or partial corpus callosum hypoplasia were detected in single cases. Eye involve-
ment was absent or mild. By genotype analysis, we defined a distinct 170kb haplotype encom-
passing POMT2 and shared by all the subjects harboring the mutation p.Tyr666Cys.
Conclusions: Our results broaden the clinical spectrum associated with POMT2 mutations, which
should be considered in patients with CMD associated with microcephaly, and severe mental
retardation with or without ocular involvement. Neurology® 2007;69:1254–1260
Congenital muscular dystrophies (CMDs) are a heterogeneous group of inherited myop-
athies, most of them with autosomal recessive transmission. They are characterized clin-
ically by early onset hypotonia, weakness, and delayed motor development, and
morphologically by the finding of dystrophic changes on the muscle biopsy.1,2 Spinal
deformities and joint contractures are frequently observed in the course of the disease.
There exist a number of entities which associate CNS abnormalities and variable eye
involvement, in addition to the muscular dystrophy: Fukuyama congenital muscular dys-
trophy (FCMD: OMIM 253800), muscle-eye-brain disease (MEB: OMIM 253280),
Walker-Warburg syndrome (WWS: OMIM 236670), and congenital muscular dystro-
phies MDC1C (OMIM 606612) and MDC1D (OMIM 608840). Intense research in the
last few years has revealed that these forms share a common pathogenic mechanism
linked to the abnormal glycosylation of alpha-dystroglycan (-DG), and are thus called
secondary alpha-dystroglycanopathies. They are caused by mutations in at least six genes
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encoding enzymes: fukutin (FKTN), pro-
tein O-mannose beta-1,2-N-acetylglu-
cosaminyltransferase (POMGNT1), protein
O-mannosyltransferase 1 (POMT1), protein
O-mannosyltransferase 2 (POMT2),
fukutin- related protein (FKRP), and
acetylglucosaminyltransferase-like protein
(LARGE).3-8 The functions of these pro-
teins are being elucidated. POMT1 and
POMT2 are responsible for the catalysis of
the first step inO-mannosyl glycan synthesis
in endoplasmic reticulum,9 and POMGnT1
catalyzes the transfer of N-acetylglucos-
amine from UDP-GlcNAc to O-mannosyl
glycoproteins in the Golgi apparatus.4
Recessive mutations in either POMT1
or POMT2 causeWWS.10-14 POMT1muta-
tions may also result in phenotypes milder
than severe WWS. These include limb-
girdle muscular dystrophy with early onset
mental retardation, with or without minor
brain abnormalities.14-17 While the first
three homozygous POMT2 mutations
were described in typical WWS patients,18
two compound heterozygous missense mu-
tations were recently reported in a girl with
a MEB-like phenotype.19
In the present study, we identified new
POMT2 mutations in CMD patients with
mental retardation.
METHODS Blood samples were obtained from CMD pa-
tients and family members. Informed consent for genetic
analysis was obtained according to the ethics committee of
our institutional review board. Specimens for light micros-
copy were immediately frozen and processed using standard
histologic and histochemical techniques according to previ-
ously described procedures.20
Immunohistochemistry analysis. Unfixed frozen 8 m
sections were incubated with monoclonal antibodies to dys-
trophin (NCL-DYS1-3), sarcoglycan (NCL--SARC), mer-
osin (80kD, Chemicon; 300 kD, NCL-merosin), -DG
(NCL- -DG), and glycosylated -DG (VIA4-1, Upstate,
USA). They were then revealed with a biotinylated second-
ary antibody followed by streptavidin conjugated to molecu-
lar probes, and were visualized with epifluorescence
microscopy.
Immunoblot analysis. Muscle proteins were extracted in
sample buffer, and transferred to nitrocellulose membrane
by electrophoresis. The membranes were blocked, and
probed with antibodies to -DG. They were then washed,
incubated with monoclonal antibody II H6 (1:500, pro-
vided by Dr. Kevin Campbell), and visualized with
chemiluminescence.7
Genetic analysis. Genomic DNA was extracted using
standard methods from peripheral blood lymphocytes. Mu-
tations in FKRP, POMGNT1, and POMT1 were excluded
by direct sequencing. For POMT2, primers pairs were de-
signed to amplify the 21 coding exons and flanking intronic
sequences. Except for exons 1, 17, 18, 19, and 20, we used
previously described primers.18 The optimal working condi-
tions were determined by running a gradient PCR. The
primer sequences and PCR conditions are available on re-
quest. The amplification products were purified and directly
sequenced with the BigDye Terminator v3.1 Cycle Sequenc-
ing Kit (Perkin Elmer Applied Biosystems). Sequences were
analyzed on an ABI PRISM 3730 capillary sequencer (Ap-
plera, CA). The presence of the mutation c.1997AG
(p.Tyr666Cys) was confirmed by restriction enzyme analysis
with Bts1 (New England Biolabs) on the PCR products with
the following primers: ACAGCAAGGAAGGGGCAGAG
and TGCTCTGTCTCCCAAGTCCAG and by single
strand conformation analysis (SSCP). This method was used
to screen the absence of the mutation in 100 unrelated Euro-
pean control individuals.
Haplotype analysis. Haplotype analysis was performed
in all patients carrying the c.1997AG POMT2 mutation
and their family members. All of them were typed for six
extragenic microsatellites markers, and five intragenic single
nucleotide polymorphisms (SNPs). As shown in figure E-1
(on the Neurology® Web site at www.neurology.org), the
POMT2 gene is found in a telomeric to centromeric orienta-
tion, and the extragenic microsatellite markers were located
close to POMT2 as follows: cen-D14S279-D14S983-
CA1_POMT2 (GT repeats)-POMT2-CA3_POMT2 (GT
repeats)-CA4_POMT2 (CA repeats)-D14S59–tel. Based on
the annotated genomic assembly (http://www.ensembl.org/
index.html), D14S279 and D14S983 are at a distance of 310
and 220 kb from POMT2, and D14S59 is 290 kb away. We
identified and analyzed new informative microsatellite
markers closer to POMT2: CA1_POMT2 located 80 kb cen-
tromeric (downstream to the transcriptional orientation of
POMT2); CA3_POMT2 (40 kb telomeric); and
CA4_POMT2 (50 kb telomeric). Primer sequences of
CA1_POMT2, CA3_POMT2, and CA4_POMT2 were as
follows: CA1_POMT2 (forward) 5=-ACACCCAGAG-
AGGAGGAGTG-3=, (reverse) 5=-AGGTCACATTCCA-
TGCTTCC-3=, CA3_POMT2 (forward) 5=-GGGCG-
ACAGAGCAAGACTC-3=, (reverse) 5=-CCTGGG-
TGATGGAGTGAGG-3=, and CA4_POMT2 (forward)
5=-CCTGCATCAGCCTCTCAAGT-3=, (reverse) 5=-TCCT-
CCCATGTCAGTCCCTA. The PCR products were analyzed
on the ABI PRISM 310 (Perkin Elmer).
RESULTS Patients. Clinical features and labora-
tory data of the four patients are summarized in
the table. Patient 1 died at age 24 years due to
respiratory failure; the three other patients re-
main alive. The four patients had a number of
major clinical features in common. At birth, each
presented with congenital hypotonia and micro-
cephaly, and psychomotor development was de-
layed in the early stages. All of them were severely
mentally retarded. Upon examination, all had mi-
crocephaly; severe diffuse weakness including the
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face, trunk, and girdle muscles; tongue and calf
muscle hypertrophy; diffuse joint contractures;
and diminished or absent deep tendon reflexes. In
addition, except for Patient 4 (who was only 6
years old at examination), all showed severe spi-
nal deformity with marked fixed hyperextension
of cervical, dorsal, and lumbar regions (figure 1).
There are, however, some variations in the
presence and severity of clinical features among
the four patients. Only one patient (Patient 2)
gained the ability to sit unaided (at age 1 year);
she also was able to walk without support at age
2.5 years, but lost ambulation at age 10 years. Al-
though all patients could understand simple or-
ders, only one patient (Patient 3) could speak
about 20 words (although he was not able to
make sentences). Patients 1 and 4 had bilateral hip
dislocation, and Patient 4 underwent surgery at
age 5 years for correction. Only one patient (Pa-
tient 2) had significant ophthalmologic findings,
consisting of retinal peripheral abnormal pigmen-
tations; the other three patients had no or mild
ocular involvement, without ocular malforma-
tion or retinal dysplasia. Only one patient (Pa-
tient 1) had cardiac involvement, consisting of left
ventricular hypertrophy as shown by echocardio-
gram at age 3.5 years, but it was not progressive.
Brain MRI documented moderate or mild ce-
rebral cortex atrophy in four patients, consisting
of moderate enlargement of the lateral ventricles
(Patient 1), hypoplasia of the median and poste-
rior regions of corpus callosum (Patient 2), and
localized T2 hypersignal lesions in the occipital
periventricular white matter (Patient 3). All four
patients showed moderate or mild cerebellar ver-
mis hypoplasia without any brainstem involve-
ment (figure 2). Serum CK levels were markedly
elevated, from 2.5 to 100 times the upper limit of
normal. Electromyogram (EMG) showed myo-
pathic changes. Muscle CT, performed in Patient
1 at age 22 years, showed severe diffuse wasting
and low density of the axial and limb muscles
with relative preservation of the anterior tibial
muscles. In the four cases, muscle biopsies re-
vealed dystrophic changes with variability of fiber
size, replacement of myofibers by fat and connec-
tive tissue, type-1 fiber atrophy, and necrotic or
regenerative fibers.
Immunohistochemistry. Immunohistochemistry
analysis of muscle biopsies showed some irregu-
larity in the laminin 2 chain labeling, upregula-
tion of the laminin 5 chain in two patients
(Patients 2 and 4), and a drastic and diffuse reduc-
tion of the glycosylated -DG labeling on almost
all the muscle fibers in three patients (Patients 1,
2, and 4) (figure 3). Immunolabeling of dystro-
phin, sarcoglycan, merosin, dysferlin, caveolin-3,
collagen VI, lamin A/C, emerin, and -DG was
normal. In Patient 3 the expression of laminin 2
chain was normal, but insufficient muscle was
available to assess -DG status.
Immunoblot analysis. Immunoblot analysis of
muscle specimens showed that the pattern of gly-
cosylated forms of -DG (a dispersed, dense band
of 156 kDa) was drastically reduced in Patients 1,
2, and 4, compared to control samples, suggesting
defective glycosylation (data not shown). Immu-
Table Clinical features of patients with congenital muscular dystrophies
Patient 1 Patient 2 Patient 3 Patient 4
Current age, y Died at 24 27 14 6
Gender Female Female Male Male
Origin Moroccan French Sicilian/French French
Consanguinity Unknown No No No
Congenital hypotonia Yes Yes Yes Yes
Maximum motor function Sits unaided Ambulant between
ages 2.5–10 y
Sits unaided Sits unaided
Mental retardation Yes Yes Yes Yes
Microcephaly Yes Yes Yes Yes
Ocular involvement No Retinal peripheral abnormal
pigmentations
Mild myopia Mild strabismus
Brain MRI
Cerebral cortex atrophy Mild, predominantly
in the parietal area
Discrete and diffuse Mild Moderate, predominantly
in the frontal-temporal area
Cerebellar vermis hypoplasia Yes Mild Mild Moderate
Brainstem involvement No No No No
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noblot analysis was not performed on Patient 3.
Mutation detection. The same homozygous muta-
tion, c.1997AG, in exon 19 of POMT2 was
identified in Patients 1 and 2 (figure E-2A). This
mutation leads to the substitution of tyrosine at
position 666 to cysteine (p.Tyr666Cys), and gen-
erates a new BtsI restriction site. The parents of
Patient 2 harbored the mutation in the heterozy-
gous state (figure E-2B). Amino acid alignment
shows that the tyrosine 666 is conserved in verte-
brate POMT2 and POMT1 orthologues, and
even in more distantly related orthologues such as
Drosophila melanogaster (figure E-2C). The same
mutation was also found in the heterozygous
state in Patients 3 and 4, and a novel mutation
was also detected in each. Patient 3 had a novel
nonsense mutation (c.1941GA, p.Trp647X) in
exon 19. Patient 4 had a novel missense mutation
(c.2242TC, p.Trp748Arg) in exon 21. One dis-
ease allele was carried by each parent of Patients 3
and 4. The c.1997AG was also identified in the
heterozygous state in four additional CMD pa-
tients from France or Spain, for whom we did not
find a second mutation (data not shown), but not
found in 200 alleles from healthy unrelated indi-
viduals, as well as the two other mutations.
Haplotype analysis. Six microsatellite markers and
five intragenic SNPs were genotyped in families
carrying at least one heterozygous c.1997AG
POMT2 mutation to determine whether it is in-
herited on the same genetic background (figure
E-1). As seen in figure E-3, the four families
shared the same haplotype, limited by
CA1_POMT2 and D14S59, on the allele harbor-
ing the c.1997AG mutation. Different back-
grounds are associated with the two other
mutations as shown by the haplotypes either
transmitted to Patient 3 by his father (who carries
the c.1941GA mutation) or to Patient 4 by his
mother (who carries the c.2242TC mutation).
The four other families in which we identified
c.1997AG as the sole disease allele shared most
of the common haplotype, with the exception of a
recombination at CA4_POMT2 in three families.
Thus the disease-associated haplotype as defined
by the minimum combination of three microsatel-
lites and five SNPs is (CA1_POMT2) 231-C-G-G-
C-T-249-205 (CA4_POMT2). This common
haplotype was not found in any parental chromo-
some without the c.1997AG mutation.
DISCUSSION Defects in O-glycosylation of
-DG are associated with a broad spectrum of
autosomal recessive CMDs, from forms without
CNS involvement and with a benign course to
forms with structural brain and eye abnormali-
ties, absent motor development, and early
death.1,2 The most severe form is the Walker-
Warburg syndrome (WWS) in which CMD is as-
sociated with CNS abnormalities including type II
cobblestone lissencephaly, hydrocephalus, brain-
stem and cerebellar malformations, and eye
anomalies. Most children with WWS die before
the age of 3 years.21 At present, up to 20% of
WWS cases have identifiable defects in POMT1
or POMT2, and only rare cases have been associ-
ated with mutations in FKTN and FKRP; the ge-
Figure 1 Patients
(A) Patient 1 at age 22 years. (B) Patient 2 at age 2.5 years (B-1) and 20 years (B-2). (C)
Patient 3 at age 10 years. (D) Patient 4 at age 6 years. Note the lower limb (particularly calf)
muscle hypertrophy, facial muscle weakness, and the open mouth in all patients. Patients 1,
2, and 3 have cervical-dorsal lordosis, with stiff hyperextended necks. In Patient 1, this is
associated with lumbar lordosis. Patient 4 has slight strabismus.
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netic cause in the remainder of WWS cases is
unknown.10,11,18,22-24 In POMT2, only three ho-
mozygous mutations have been reported to date
in WWS patients (two nonsense mutations and
one splice site mutation),18 along with two com-
pound heterozygous missense mutations in a
MEB-like patient.19
Here, we identified the common missense mu-
tation in POMT2 (c.1997AG, p.Tyr666Cys) in
the homozygous state in two unrelated patients.
The same heterozygous mutation was found in
two other patients, associated with two new
POMT2 mutations (c.1941GA, p.Trp647X and
c.2242TC, p.Trp748Arg). All four patients who
were either homozygous or heterozygous for the
p.Tyr666Cys mutation presented with CMD as-
sociated with microcephaly and severe mental re-
tardation, but they had only mild structural CNS
abnormalities revealed by the brain MRI (cere-
bral atrophy and cerebellar vermis hypoplasia),
and only three of them had minor ocular abnor-
malities even at late ages (abnormal pigmentation
of the peripheral retina, myopia, or strabismus),
in contrast with WWS and MEB.
Other than the neurologic findings, the pa-
tients showed several clinical features often ob-
served in patients with secondary alpha-
dystroglycanopathies, especially at late ages. All
patients had very high CK levels and facial and
proximal limb predominant muscle weakness.
The three patients older than 10 years showed a
progressive motor and respiratory insufficiency,
and diffuse joint contractures. In spite of having
the same gene defect, both patients carrying the
homozygous mutation had marked variability in
the severity of motor dysfunction, suggesting ad-
ditional influencing factors. While one patient
never walked and died in young adulthood due to
respiratory insufficiency, another was able to
walk without support at age from 2 to 10 years
and at 22 years had a respiratory insufficiency but
did not require mechanical ventilation. Interest-
ingly, in all patients older than 10 years, axial
muscle weakness led to a very similar spinal lor-
dotic deformity characterized by a marked fixed
hyperextension of the cervical, dorsal, and lum-
bar spine. This type of deformity is partly due to
the occurrence of neck and paravertebral exten-
sor muscle contractures in the absence of strong
neck flexor muscles. In our experience, it is not
infrequent in the course of early onset muscular
dystrophies, especially those due to mutations in
LAMA2, SEPN1, and LMNA. However, this sort
of deformity has not been previously described in
patients with dystroglycanopathy, even at very
late stages of the disease. This could be due to the
early death of most patients, to differences in or-
thopaedic treatment among patients, or to incom-
plete data regarding this specific feature in
previous publications. Further clinical reports
will be therefore required to elucidate if this is a
distinct feature of POMT2mutations.
Compared with previously reported patients
with congenital dystroglycanopathies, the pheno-
type observed in our first patient is different from
the MEB phenotype because our patient had
brain atrophy and posterior fossa malformation
but no eye involvement. Her clinical and neurora-
diologic picture was close to that described in cer-
tain FKRP mutated patients with mental
retardation and CNS malformation,25-27 although
no brainstem hypoplasia or cerebellar cysts were
observed in our patient compared to the FKRP
patients. Our remaining three patients had mild
eye involvement and minor CNS abnormalities,
and therefore can be considered as a mild “MEB-
like phenotype,” very similar to that described in
a series of four Italian patients with CMD, mental
retardation, microcephaly, and calf and thigh en-
Figure 2 Brain MR images
T2-weighted axial (A-1 and B-1) and T1-weighted sagittal (A-2 and B-2) brain MR images of
Patient 3 at 5 years old (A) and Patient 4 at 6 years old (B). The MRI of Patient 3 shows
hypersignal lesions at the occipital periventricular white matter (A-1, arrow), mild hypoplasia
of the cerebellar vermis (especially the inferior part) without brainstem abnormalities (A-2),
and mild atrophy of the frontal and temporal cerebral cortex (A-1). Patient 4 demonstrates
moderate cortical atrophy, predominantly in the frontal and temporal cortex (B-1 and B-2).
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largement.28 Subsequently, four different POMT1
missense or nonsense mutations were identified in
three of them.14 Recently, two POMT2 missense
mutations (p.Gly353Ser and p.Gly726Glu) have
been identified in the fourth patient, who pre-
sented with microcephaly, severe mental retarda-
tion, muscle hypertrophy, diffuse muscle
weakness with marked facial and proximal limb
involvement, and mild myopia. Neuroradiologi-
cally, cortical-subcortical brain atrophy, pons
and cerebellar vermis hypoplasia, and abnormal
signal of the periventricular white matter were
observed.19 It is not surprising that patients with
POMT1 and POMT2 mutations could share the
same phenotype because POMT1 and POMT2
form a heterodimeric complex responsible for the
catalysis of the first step in O-mannosyl glycan
synthesis.9
In the present study, although two patients
harbored homozygous copies of the same muta-
tion, the patients were unrelated, and none of the
families was known to be consanguineous. In this
setting, by analysis of the chromosomal back-
ground upon which a mutation occurs, one can
infer whether a specific disease-causing mutation
is due to a founder effect. Genotype data defined
a distinct 170 kb haplotype encompassing
POMT2 and shared by all the subjects harboring
the p.Tyr666Cys mutation. These results suggest
that this mutation is a founder mutation present
in the European population. Further studies will
be needed to determine its precise geographic ori-
gin and frequency. This study provides confirma-
tion that, as reported for other forms of alpha-
dystroglycanopathies, POMT2 mutations are
associated with a wide clinical and neuroradio-
logic heterogeneity. In addition to the previous re-
ported phenotypes including WWS and MEB-
like, our results demonstrate that POMT2
mutations may be responsible for a CMD associ-
ated with mental retardation and posterior fossa
hypoplasia but no ocular involvement, similar to
the phenotype previously described in patients
with FKRP mutations and CNS involvement.
Variable phenotypic severity was observed in pa-
tients with the same genotype, suggesting the in-
fluence of additional pathogenic factors.
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